摘要
目的探讨托拉塞米联合小剂量多巴胺治疗慢性心力衰竭患者的临床效果。方法选取2019年1—12月沈阳急救中心收治的98例慢性心力衰竭患者作为研究对象,随机分为对照组与观察组,各49例。对照组在常规治疗基础上加用托拉塞米,观察组在对照组基础上联合小剂量多巴胺治疗。比较两组患者的心功能指标、肾功能指标、心力衰竭改善情况及不良反应发生情况。结果治疗后观察组脑钠肽(BNP)、Tei指数、6 min步行试验(6MWT)优于对照组,差异有统计学意义(P<0.05);治疗后两组患者肾功能指标明显改善,且观察组血肌酐(Scr)、尿素氮(BUN)、白蛋白(ALB)及内生肌酐清除率(Ccr)优于对照组,差异有统计学意义(P<0.05);观察组住院时间短于对照组,利尿剂抵抗及肾功能恶化发生率低于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为10.20%,与对照组的14.29%比较,差异无统计学意义(P>0.05)。结论托拉塞米联合小剂量多巴胺治疗慢性心力衰竭临床疗效显著,能有效改善患者心肾功能,安全可靠。
Objective To explore the clinical effects of tolasemide combined with low-dose dopamine in the treatment of chronic heart failure. Methods A total of 98 cases were selected from January 2019 to December 2019 in Shenyang Emergency Center and were randomly divided into a control group and an observation group. The control group was given the conventional therapy plus tolasemide, and the observation group was treated with low-dose dopamine on the basis of the control group. The laboratory indexes such as cardiac function, renal function, improvement of heart failure and occurrence of adverse reactions were compared between the 2 groups. Results After treatment, the brain natriuretic peptide(BNP), Tei index, and 6-minute walking test(6 MWT) were better than the control group, and the difference was statistically significant(P<0.05);after treatment, the renal function indexes of the 2 groups of patients were significantly improved and serum creatinine(Scr), urea nitrogen(BUN), albumin(ALB) and endogenous creatinine clearance(Ccr) in the observation group were better than the control group. The difference was statistically significant(P<0.05);the observation group had fewer days in hospital than the control group, the incidence of diuretic resistance and deterioration of renal function was lower than the control group, with significant difference(P<0.05);the incidence of adverse reactions was 10.20% in the observation group and 14.29% in the control group(P>0.05). Conclusion Torasemide combined with low-dose dopamine in the treatment of CHF has satisfactory clinical efficacy, and can effectively improve the heart and kidney function of patients, which is safe and reliable.
作者
兆欣
高兴
李德伟
ZHAO Xin;GAO Xing;LI De-Wei(Shenyang Emergency Center,Shenyang 110006.China)
出处
《中国药物经济学》
2020年第6期72-75,共4页
China Journal of Pharmaceutical Economics
